INTRODUCTION
============

Over the past decades, the survival rate for childhood cancer has increased substantially. This can be explained by more effective chemotherapy regimens. Improvement in survival has led to delayed emergence of sequelae in long-term survivors such as heart failure, infertility, or risk of secondary malignancy. Furthermore, several studies have shown an association between cancer treatments such as radiotherapy and/or chemotherapy and dental developmental abnormalities, including agenesis, root stunting, and enamel defects. Indeed, radiation interferes with the dental development by directly inhibiting the mitotic activity of odontoblasts. Although the risk of dental abnormalities after radiotherapy is well described, the factors associated with long-term dental effects after chemotherapy for childhood malignancies are less known. Chemotherapies received during dental development affect odontogenesis and amelogenesis in childhood malignancy survivors. These anomalies are described in children treated for solid tumors^[@B1]^ or hematological malignancies^[@B2]^ such as acute lymphoid leukemia. Although these anomalies represent half of childhood cancers, acute myeloid leukemia (AML) occurs only in 15 to 20% of acute leukemia cases^[@B3]^ and long-term side effects involving tooth development are not often reported. Here, we report the case of a nine-year-old boy treated for AML at 15 months of age, who presents several dental abnormalities resulting from anticancer treatments.

CASE DESCRIPTION
================

A young patient was diagnosed with acute myeloid leukemia (AML) at 15 months of age. He was included and treated according to the ELAM 02 French protocol. This treatment protocol contains induction chemotherapy with aracytine and novantrone, each course lasting 7 days and 5 days, respectively. The first complete remission was obtained so that the induction chemotherapy was followed by three courses of consolidation chemotherapy. The patient received aracytine, amsacrine, daunorubicin, etoposide, and [l]{.smallcaps}-asparaginase. Six months after the end of chemotherapy, a bone-marrow relapse was diagnosed. The patient received a new induction chemotherapy with the FLAG scheme (fludarabine, high-dose aracytine, and G-CSF). Due to poor response, a second-line induction chemotherapy with the IDAFLAG scheme (idarubicin, fludarabine, and high-dose aracytine) was administrated to the patient, leading to a complete response. The doses of chemotherapeutic agents are listed in [Table 1](#T1){ref-type="table"}. Allogeneic hematopoietic stem cell transplantation (allo-HCT) was then performed after a myeloablative conditioning, including busulfan (1.2 mg/kg/ × 4 per day × 4 days) and cyclophosphamide (50 mg/kg/day × 4 days). The patient received cyclosporine, methotrexate, and anti-thymoglobulin for graft vs host disease (GvHD) prophylaxis. He developed grade II-acute gastrointestinal tract and skin GvHD treated with steroids and mycophenolate mofetil, and then extensive chronic GvHD (gut, skin, and lungs), which required multiple immunosuppressive drugs (mycophenolate mofetil, infliximab, rituximab, tacrolimus, basiliximab, and steroid therapy for 2 years) associated with extracorporeal photochemotherapy, antibiotic prophylaxis (amoxicillin), and anti-viral drug (zovirax). The patient also suffered from pulmonary aspergillosis and mucormycosis treated with antifungal therapy (amphotericin B, voriconazole, caspofungin).

###### 

Doses of chemotherapeutic agents according to the patient received

  ---------------------------- ------------------------------ ---------------------------------
  Induction chemotherapy                                      
  Aracytine                    200 mg/m^2^/day × 7 days       
  Novantrone                   10 mg/m^2^/day × 5 days        
  Consolidation chemotherapy                                  
  No. 1                        Aracytine                      3 g/m^2^ × 2/day × 3 days
  Amsacrine                    100 mg/m^2^ × 2/day × 3 days   
  No. 2                        Aracytine                      200 mg/m^2^/day × 4 days
  Daunorubicine                40 mg/m^2^/day × 4 days        
  Etoposide                    100 mg/m^2^/day × 4 days       
  No. 3                        Aracytine                      3 g/m^2^ × 2/day D1, D2, D8, D9
  L-asparaginase               6000 U/m^2^/day D2, D9         
  FLAG                                                        
                               Fludarabine                    30 mg/m^2^/day from D2 to D6
  Aracytine                    2 g/m^2^/day from D2 to D6     
  G-CSF                        From D1 to D6                  
  IDAFLAG                                                     
                               Idarubicin                     8 mg/m^2^/day D2, D4, J6
  Fludarabine                  30 mg/m^2^/day from D2 to D6   
  Aracytine                    2 g/m^2^/day from D2 to D6     
  G-CSF                        From D1 to D6                  
  ---------------------------- ------------------------------ ---------------------------------

Six years after allo-HCT, the patient was referred to the Department of Pediatric Dentistry. The intraoral examination revealed structural anomalies such as enamel defects located at the permanent maxillary and mandibular central and lateral incisors and canines ([Fig. 1A](#F1){ref-type="fig"}).

![(A) Enamel defects located at the permanent incisors and canines in a nine-year-old patient treated for AML with chemotherapies and allo-HCT at 15 months of age; (B) Resin composite restorations (Tetric EvoCeram® A2, Ivoclar Vivadent) of the permanent maxillary incisors and canines 9 months after the restorations were performed](ijcpd-12-243-g001){#F1}

![Dental panoramic radiograph: agenesis of the second permanent molars and three second premolar (asterisks), microdontia of the first premolars (white arrows), root stunting of the maxillary and mandibular central incisors and first premolars (black arrows), and rootlessness of the first permanent molars (arrow heads) in a nine-year-old patient treated for AML](ijcpd-12-243-g002){#F2}

The dental panoramic radiograph ([Fig. 2](#F2){ref-type="fig"}) showed several dental developmental abnormalities including agenesis of the second permanent molars and three second premolars, microdontia of the first premolars, root stunting of the maxillary and mandibular central incisors and first premolars, and rootlessness of the first permanent molars. Dental examination was completed by an orthodontic examination for advice regarding his malocclusion. Orthodontic treatment was contraindicated due to the arrested tooth development and short roots. The risk of root resorption was considered too important. As a first step to reduce enamel defects, we proposed to perform restorations with resin composite (Tetric EvoCeram® A2, Ivoclar Vivadent) after micro-abrasion realized under a dental dam ([Fig. 1B](#F1){ref-type="fig"}). The patient and his parents accepted only the restorations of the permanent maxillary incisors and canines. A systematic scheduling of a dental follow-up in parallel with the onco-hematologic follow-up was established. The objectives were (1) maintaining the primary teeth on the dental arch as long as possible (initiate a preventive treatment that contains application of fluorinated varnish and filling the grooves of the occlusal face for example, the purpose being to avoid the development of carious lesions), (2) observing the eruption of permanent teeth to detect structural anomalies, (3) evaluating the mobility of permanent teeth with short roots, (4) proposing a prosthetic treatment to replace missing teeth, prevent disorders in orofacial functions and promote the bone growth, and (5) meeting expectations of the patient and his parents. On the prosthetic plan, a removable prosthesis could be indicated and must be regularly adjusted to the bone growth. The bone remodeling process and the bone growth are considerable and do not allow the placement of implant during this period of growth. Implant therapies must be postponed and considered when the bone growth is complete.

DISCUSSION
==========

Proc *et al.*^[@B4]^ showed that dental abnormalities were most frequently observed in cancer survivors than in healthy patients (62% vs 13%, *p* value \< 0.0001). Cytotoxic molecules at the time of early dental development may result in agenesis, microdontia, and enamel defects, while effects of antineoplastic agents in the later stages of formation are characterized by the anomalies of root formation.^[@B5]--[@B7]^ Considering the sequence of dental calcification and development,^[@B8]^ children between 0 and 5 years of age seem to be at the highest risk of several dental abnormalities resulting from anticancer treatments. Indeed, several studies reported an age-specific risk for dental abnormalities.^[@B5],[@B9]--[@B11]^ This explains the important number of missing teeth and the enamel defects observed in our patient, who received cancer treatment at 15 months of age.

It is given that chemotherapies include several molecules, and it is difficult to determine the independent effects of each antineoplastic agent on dental anomalies. However, previous studies have identified that cyclophosphamide and vincristine are associated with dental developmental disturbance in the survivors of childhood malignancies.^[@B1],[@B9],[@B10]^ Furthermore, several studies reported that children conditioned with total body irradiation (TBI) and high dose chemotherapy (cyclophosphamide and busulfan) before HCT are at high risk for dental developmental abnormalities.^[@B12],[@B13]^ Considering this data, our patient, who received myeloablative doses of busulfan and cyclophosphamide for HCT, was at a high risk for long-term several dental abnormalities. His clinical picture confirms this hypothesis. It has also been suggested that the early use of antibiotics (amoxicillin) under the age of 4 years can disturb dental hard tissue formation and lead to enamel defects such as molar incisor hypomineralization (MIH),^[@B14]^ but the etiology of MIH is still unclear. In our patient, antibiotic prophylaxis (amoxicillin) was associated with the treatment of the GvHD from 2.5 to 8 years of age. To date, there has been no reported case of dental abnormalities such as agenesis, root stunting, microdontic teeth or enamel defects associated with immunosuppressive therapy in children. This case clearly illustrates the extent of oral late side effects of anticancer treatment in the survivors of childhood cancer and confirms that the severity of dental abnormalities is influenced by both younger ages at chemotherapy and by high doses of some antineoplastic agents and maybe some antibiotic and immunosuppressive therapies.

The impact of odontogenesis disturbance is also psychological. Dental anomalies in childhood cancer survivors are obviously not life-threatening complications, but they can impair the quality of life of teenagers and young adults. The occurrence of these dental anomalies is a reminder of cancer pathology, as they are a visible stigma. Dental anomalies decrease masticatory functions, maxillary bone growth, and may lead to orthodontic troubles but also impact the aesthetic view of the anterior region, especially enamel defects. A study showed that young people may make negative psychosocial judgments on the basis of enamel appearance.^[@B15]^ Enamel defects should not be ignored and the practitioner should pay attention to the dental anomalies as far as the appearance of some enamel defects can be improved by simple non-invasive procedures such as micro-abrasion and composite restorations.^[@B16]^

More knowledge into the prevalence of these adverse late effects and risk factors associated is necessary to determine and prevent dental abnormalities to inform and provide support to the patient and his family.

CLINICAL SIGNIFICANCE
=====================

A twice yearly dental examination carried out by a dental surgeon experienced in survivorship care, as recommended by the Children\'s Oncology Group guidelines,^[@B17]^ should be a part of medical follow-up monitoring late effects in long-term survivors of childhood cancer. This case illustrates the importance of systematically scheduling a dental follow-up in parallel with the onco-hematologic follow-up allowing the clinicians to prevent, detect, and propose early intervention of dental late effects.
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